Alexander Romaschin

PhD, FCACB, DCC

Investigator

Biography

Dr. Alex Romaschin is a certified Clinical Biochemist (1984) and Division Head of Biochemistry at St. Michael’s Hospital (2005). He developed a US FDA and Canada health protection branch approved human diagnostic test for Gram negative endotoxin (EAA) and is co-holder of 4 patents related to this assay technology. He was the co-founder of Sepsis Inc. which was a spin off biotechnology company founded in 1995 and acquired by Spectral Medical Products which commercialized the EAA assay in conjunction with an endotoxin removal hemofiltration device. His current research interests include applications of small molecule mass spectrometry to diagnostic testing, rapid detection of antibiotic resistance and design of biocompatible surfaces. His past training included a PhD in chemistry at the University of Windsor, a North Atlantic Treaty Organization sponsored postdoctoral fellowship at the Cardiovascular Research Institute University of California San Francisco and a diploma in Clinical Biochemistry at the University of Toronto. He has more than 30 years experience as a Clinical Chemist and as of 2015, his 106 peer reviewed publications have raised more than 7 million dollars in research and commercialization funding.

Recent Publications

Search PubMed

Affiliations & Other Activities

  • Head, Clinical Biochemistry, St. Michael’s Hospital
  • Associate Professor, Lab Medicine and Surgery, University of Toronto